{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:40:58Z","timestamp":1777088458055,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to characterize the effects of cedirogant, an inverse agonist of retinoic acid\u2013related orphan receptor gamma thymus (ROR\u03b3t), on activities of cytochrome P450 (CYP) enzymes in healthy adults. Twenty study participants received a single oral dose of the modified Cooperstown 5+1 cocktail CYP probe drugs alone without cedirogant (Period 1, midazolam on Day 1 and other CYP substrates on Day 2), and again following once\u2010daily dosing of 375\u00a0mg cedirogant (Period 2, cedirogant on Days 1\u201018, midazolam on Day 13, and other CYP substrates on Day 14). Blood samples and 12\u2010hour urine samples were collected to measure the exposures of the CYP probe drugs and selected metabolites. The point estimates (90% confidence intervals) of the area under the plasma concentration\u2013time curve from time 0 to infinity (AUC\n                    <jats:sub>inf<\/jats:sub>\n                    ) ratio with and without cedirogant co\u2010administration were 0.370 (0.325\u20100.420) for midazolam (CYP3A), 1.161 (1.031\u20101.307) for caffeine (CYP1A2), and 0.788 (0.761\u20100.816) for S\u2010Warfarin (CYP2C9). The estimated ratios of plasma metabolite\/parent AUC ratio for omeprazole (CYP2C19) and parent\/metabolite molar urine recovery ratio for dextromethorphan (CYP2D6) with versus without cedirogant co\u2010administration were 2.115 (1.813\u20102.467) and 0.951 (0.802\u20101.128), respectively. Based on these findings, once\u2010daily administration of 375\u2010mg cedirogant showed moderate induction of CYP3A and CYP2C19, a weak effect on CYP2C9, and no clinically relevant effects on CYP1A2 or CYP2D6.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70059","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:51:52Z","timestamp":1776664312000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates"],"prefix":"10.1002","volume":"15","author":[{"given":"Ronilda","family":"D'Cunha","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[{"name":"Discovery and Exploratory Statistics AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Eccleston","sequence":"additional","affiliation":[{"name":"Immunology Clinical Development AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gweneth F.","family":"Levy","sequence":"additional","affiliation":[{"name":"Global Patient Safety AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikanth","family":"Gannu","sequence":"additional","affiliation":[{"name":"Regulated Bioanalysis AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Regulated Bioanalysis AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed\u2010Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1948833"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae152"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13682"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1386"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.158"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1496"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1377"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3399"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90237-2"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90194-0"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00410.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90116-8"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00630.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04310.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00122.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(96)00140-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145798001187"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70059","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:08:43Z","timestamp":1777086523000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/cpdd.70059"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70059","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70059"}}